Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

NCT Number	NCT07654179
Lead Sponsor	Riphah International University
Conditions	Depression, Depressive Disorder, Overweight or Obesity, Depressive Symptoms
Enrollment	200 participants
Start Date	2026-06-17
Primary Completion	2027-06-11 (estimated)
Study Completion	2027-06-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-07